Cybin (HELP) Stock Price, News & Analysis

Company Overview

Cybin Inc. is a clinical-stage biotechnology company focused on developing psychedelic-based therapeutics for mental health conditions. The company combines psychedelic compounds with drug-delivery technologies and treatment protocols designed to improve the safety, consistency and duration of psychedelic-assisted therapies.

Cybin’s development programs have included CYB003, an investigational deuterated psilocybin therapy being studied for major depressive disorder, and CYB004, an investigational formulation of N,N-dimethyltryptamine (DMT) being evaluated for generalized anxiety disorder. Its programs are intended to support shorter, more controlled treatment sessions than traditional psychedelic therapies.

Founded in 2019 and headquartered in Toronto, Cybin has conducted research and clinical-development activities in North America and the United Kingdom. The company has been led by Chief Executive Officer Doug Drysdale, who has experience in biotechnology and pharmaceutical development. Cybin’s shares have historically traded on Nasdaq under the symbol CYBN; the symbol HELP may refer to a different listed company.

Key Stats

• Today's Range: $11.52 to $12.30
• 50-Day Range: $7.60 to $14.02
• 52-Week Range: $3.76 to $15.15
• Volume: 1.41 million shs
• Average Volume: 1.68 million shs
• Market Capitalization: $921.73 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $46.33
• Consensus Rating: Buy

Cybin Stock Analysis - MarketRank™

Cybin scored higher than 89% of companies evaluated by MarketBeat, and ranked 39th out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Buy

Consensus Rating

Cybin has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 6 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Cybin has a consensus price target of $46.33, representing about 296.0% upside from its current price of $11.70.

Amount of Analyst Coverage

Cybin has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cybin are expected to grow in the coming year, from ($2.95) to ($2.19) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cybin is -3.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cybin is -3.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cybin has a P/B Ratio of 2.61. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.82% of the float of Cybin has been sold short.

Short Interest Ratio / Days to Cover

Cybin has a short interest ratio ("days to cover") of 2.33, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cybin has recently increased by 6.80%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cybin does not currently pay a dividend.

Dividend Growth

Cybin does not have a long track record of dividend growth.

News and Social Media

• Score: 4.4 / 5
• News Sentiment: 1.04

News Sentiment

Cybin has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Cybin this week, compared to 4 articles on an average week.

Search Interest

35 people have searched for HELP on MarketBeat in the last 30 days. This is an increase of 46% compared to the previous 30 days.

MarketBeat Follows

27 people have added Cybin to their MarketBeat watchlist in the last 30 days. This is an increase of 125% compared to the previous 30 days.

Company Ownership

• Score: 4.3 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

4 insiders have purchased shares of Cybin in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $8,422,830.00 in company stock, which represents 0.9138% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Cybin insiders have bought more of their company's stock than they have sold. Specifically, they have bought $8,422,830.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

15.00% of the stock of Cybin is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

17.94% of the stock of Cybin is held by institutions.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 10/03/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:HELP
• Previous Symbol: CBOE:HELP
• CIK: 1833141
• Web: www.helus.com
• Phone: (908) 764-8385
• Fax: N/A
• Employees: 100
• Year Founded: 2019

Price Target and Rating

• Average Price Target for Cybin: $46.33
• High Price Target: $95.00
• Low Price Target: $16.00
• Potential Upside/Downside: +296.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.02)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$148 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -71.78%
• Return on Assets: -64.81%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.97
• Quick Ratio: 10.97

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.49 per share
• Price / Book: 2.61

Miscellaneous

• Outstanding Shares: 78,780,000
• Free Float: 66,963,000
• Market Cap: $921.73 million
• Optionable: N/A
• Beta: 0.53